Shah Capital pushes for Novavax (NVAX) sale
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
Shah Capital is urging Novavax (NASDAQ: NVAX) board to pursue a sale, according to a Reuters report on Tuesday.
- The fund is citing a third consecutive year of poor roll-out of its COVID-19 shot.
- Shah Capital owns a 7.2% stake in the company and is the second largest shareholders.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Electra Therapeutics files for proposed IPO
- McCormick board member to resign after CFO appointment at Best Buy
- Gulf Resources gets Nasdaq notice over late quarterly filing
Create E-mail Alert Related Categories
Corporate News, Hedge Funds, Mergers and AcquisitionsRelated Entities
Shah Capital, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
